Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry

Kathrin Borchert 1*, Christian Jacob 1, Natalie Wetzel 2, Martina Jänicke 5, Egbert Eggers 3, Annette Sauer 4, Norbert Marschner 5, Julia Altevers 1, Thomas Mittendorf 1 and Wolfgang Greiner 6

Abstract

Background: The EQ-5D-5L questionnaire is used in oncology to generate health-related quality of life (HRQoL) weights and corresponding health states. The purpose was to explore the relationship between demographic and clinical characteristics and HRQoL among advanced or metastatic colorectal cancer (CRC) patients by linking clinical data of a German CRC registry to self-reported HRQoL measures from the EQ-5D-5L.

Methods: The study sample included patients with advanced or metastatic CRC currently recruited in the German Tumor Registry Colorectal Cancer. The EQ-5D-5L was administered once to patients who were at the start or at later stages of palliative treatment. Data on comorbidities, disease-specific health states, symptoms, and treatment status were drawn from the registry. Multivariate regression analyses were performed to explore the impact of patient and disease characteristics on HRQoL.

Results: In total, n = 433 questionnaires were included in the data analysis. Mean age of patients was 66.3 years and 61.2% were male. The mean EQ-5D-5L utility score was 0.82 and the mean EQ-5D-5L VAS score was 62.05. The regression analyses revealed that none of the demographic characteristics and few of the clinical characteristics, such as fatigue and pain, had a significant impact on the HRQoL.

Conclusions: The study demonstrated a reduced HRQoL of patients with advanced or metastatic CRC when compared to the general population. The symptoms fatigue and pain negatively affected the HRQoL, whereas other characteristics such as age, gender, and comorbidities did not have a significant impact on HRQoL.

Keywords: Colorectal cancer, Tumor registry, EQ-5D-5L, Patient reported outcomes, Quality of life, Data linkage

* Correspondence: kathrin.borchert@xcenda.de
1Xcenda GmbH, Hannover, Germany
Full list of author information is available at the end of the article
Background
In Germany, colorectal cancer (CRC) is the second most frequent cancer among women and the third most frequent cancer among men. Approximately one out of eight cancers in Germany affects the bowel and about 6% of the population are diagnosed with colorectal carcinoma during their lifetime. Approximately 59,000 incident cases of CRC were forecasted in Germany for the year 2018 [1]. Patients with CRC suffer from a high psychological and physical burden of disease and have a reduced quality of life due to various problems in social functioning and disease-specific symptoms [2, 3].

The EuroQoL five-dimension questionnaire using a five-level scale (EQ-5D-5L) is widely used and well-accepted in oncology to measure health-related quality of life (HRQoL) [4]. However, for patients with advanced or metastatic CRC, there are no data available reporting the influence of certain comorbidities or health states on the HRQoL.

During the German benefit assessment (AMNOG) process, clinical trial data are evaluated regarding effectiveness and safety of new drugs compared to the standard of care, but also patient surveys are assessed for quality of life measures and health states. At the moment, quality adjusted life years (QALYs) assessed by the EQ-5D are not accepted in Germany for early benefit assessments, but the Institute for Quality and Efficiency in Health Care (IQWiG) is interested in conducting studies appreciating such data. The head of the Joint Federal Committee (G-BA) has suggested to further integrate HRQoL as a main outcome in the decision making process, also stating that missing data concerning patients’ QoL will have a negative impact on the overall assessment in the future [5].

Clinical registries routinely collecting clinical data present an opportunity to link HRQoL with data about disease status.

The aim of this cross-sectional application study was to explore the relationship between patient demographic, clinical characteristics and HRQoL measured with the EQ-5D-5L among patients with advanced or metastatic CRC in Germany by linking clinical data of the German colorectal cancer registry to self-reported HRQoL measures from the EQ-5D-5L. Results could serve as a basis for further research investigating if the EQ-5D-5L is able to generate (dis)utilities to be used in e.g. cost-effectiveness modelling among patients with advanced or metastatic CRC.

Methods
Data source
This cross-sectional application study derived clinical and patient-reported data from the Tumor Registry Colorectal Cancer (TKK) recruiting patients since September 2006 and run by the International Organisation of Medical Oncology (iOMEDICO). The TKK is a large, ongoing, prospective, national registry conducted by a multicenter network of 278 office- and hospital-based medical oncologists in Germany. The TKK was reviewed and approved by the Ethics Committee of the medical association of Baden-Württemberg, Germany. Data collection and methodology have been described previously [6]. At the time of study conduct, the TKK comprised data from about 6400 individuals. Inclusion criteria for the TKK are age ≥ 18 years, histologically confirmed CRC, and signed informed consent no longer than 4 weeks after the start of systemic neoadjuvant/adjuvant treatment for nonmetastatic or first-line treatment for metastatic/inoperable disease.

Study population
The study population included histologically confirmed patients with advanced or metastatic CRC who had been recruited into the TKK since March 2014 and declared willingness to participate in patient-reported outcomes (PRO) surveys.

Data collection
Potentially relevant patient and tumor characteristics (data of birth, gender, body mass index (BMI), comorbidities, primary tumor localization, operability of primary tumor), data on treatment (type of treatment per line of palliative line of treatment, antibody category, number of previous progressions, location of metastases) and treatment outcomes, and PROs were defined by literature review and by medical experts and extracted from the database as of the database cut May 2017.

iOMEDICO routinely sent out a PRO questionnaire to registered patients (at baseline, month 2, 4, 8, 12, 16, 20, and 24 after inclusion). This questionnaire contained the Quality of Life Questionnaire Core 30 version 3.0 of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30). For our application study, the EQ-5D-5L was added to the existing PRO questionnaire. The questionnaire was delivered once per patient by postal mail as part of the next round of questionnaire delivery between November 2016 and May 2017. Patients received a prepaid reply envelope and two reminders after two and 4 weeks.

Applied questionnaires
The generic EQ-5D-5L questionnaire contains the five dimensions mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each of these dimensions is to be evaluated by five levels ranging from no problems to extreme problems. In addition, the EQ-5D-5L includes the visual analogue scale (VAS), a continuous response
scale ranging from 0 (worst possible health state) to 100 (best possible health state), to record patients’ self-rated health on the day of the interview [7, 8].

The EORTC QLQ-C30 is a questionnaire developed to assess the QoL of cancer patients. Version 3.0 includes 30 questions covering five function domains (physical, role, cognitive, emotional, and social), eight symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea), and financial impact on a four-point scale (1 = “not at all” to 4 = “very much”) as well as overall health and overall QoL on a seven-point scale (1 = “very bad” to 7 = “excellent”). The questions refer to a one-week recall period called the “past week” [3, 9–11].

Statistical methods

Utility scores from the EQ-5D-5L were calculated using a Germany-specific value set leading to scores from −0.661 (worst possible health state) to 1 (best possible health state). VAS scores were recorded directly from the scale [7]. Scores from the EORTC QLQ-C30 were calculated following the scoring manual published by the EORTC leading to scores ranging from 0 to 100, with a higher score indicating a better level of functioning (functional scale) and a higher QoL (global health status/QoL scale), but a worse level of symptoms (symptom scale) [12]. Correlation between the three scores was tested using Pearson’s as well as Spearman’s correlation coefficient.

Tobit regression was applied to model the association between patient demographic and clinical characteristics and HRQoL. The tobit regression is designed to estimate linear relationships between variables when the dependent variable is either left- or right-censored. In this study, the dependent variable was HRQoL measured by the EQ-5D-5L. The score is bounded from above by 1.0 and it is common for a significant fraction of respondents to rate themselves in full health indicating that the score is unable to discriminate among high levels of health status. Therefore, we employed a tobit model with upper censoring at 1.0 in this study [13–16].

Two ordinary least squares (OLS) regression analyses on the EQ-5D-5L VAS score and the EORTC Global Health Status/QoL score were conducted and compared to the results from the tobit model.

The tobit regression of the EQ-5D-5L utility score and the OLS regression of the EQ-5D-5L VAS score were based on 377 patients because of missing data for individual variables. The OLS regression of the EORTC Global Health Status/QoL score was based on 366 patients due to missing data for individual variables.

All presented p-values are two-sided and considered to be statistically significant at < 0.05. All analyses were performed using the statistical software SAS version 9.2.

Results

Patient selection

In total, the PRO questionnaire including the EQ-5D-5L and EORTC QLQ-C30 was sent to N = 758 patients in the study period (between November 2016 and May 2017) of which n = 535 patients (70.6%) returned the questionnaire. After exclusion of unanswered questionnaires and questionnaires with retracted patient consents of n = 32 patients, data linkage of EQ-5D-5L data and clinical registry data was performed for n = 503 patients (66.4%). During data preparation, n = 59 patients were excluded due to missing EQ-5D-5L utility scores and n = 11 patients due to missing VAS scores. In total, n = 433 patients (57.1%) were included in the final data analysis (Fig. 1).

Patient demographics and clinical characteristics

Demographics

At the time of PRO questioning, the patients were on average 66.3 years (±9.5 years) old and 61.2% of patients were male (n = 265). At the time of enrollment into the TKK registry, the mean BMI of these patients was 26.3 (±5.2).

![Fig. 1 Flowchart of patient selection](image-url)
Comorbidities
At the time of enrollment into the registry, 64.9% of the patients had at least one relevant comorbidity from the list: hypertension, adiposity, cerebrovascular disease, myocardial infarction, myocardial insufficiency, coronary heart disease, heart failure, peripheral artery occlusive disease, kidney disease, liver disease, diabetes mellitus, polyneuropathy, hemiplegia, peptic ulcer disease, urogenital disease, chronic gastric or bowel disease, thyroid disease, AIDS, anemia, connective tissue disease, dementia, tumor other than colorectal or lymphoma or leukemia, metastatic solid tumor other than colorectal. The most frequent comorbidity among the patients was hypertension (41.3%), followed by diabetes mellitus (14.6%) and thyroid disease (9.0%). Furthermore, coronary heart disease was prevalent in 8.3%, tumor other than colorectal or lymphoma or leukemia in 7.9%, chronic gastric or bowel disease in 6.7%, adiposity in 6.5%, and chronic pulmonary disease in 5.8%.

Tumor history and metastases
The primary tumor was located in the colon in 56.4% and in the rectum in 43.4% of cases. At the time of the initial diagnosis, 19.9% of the patients were diagnosed with an inoperable primary tumor. Tumor stage at primary diagnosis as classified by the Union for International Cancer Control (UICC) was I for 3.7% of the patients, II for 7.2%, III for 13.9%, and IV for 66.5%. The remaining patients (8.7%) had missing data.

About one-fifth of the patients (21.0%) had experienced at least one progression prior to questioning (16.6% with one progression and 4.4% with two or more progressions). At the time of last documentation before EQ-5D-5L questioning, 61.4% of patients had liver metastases, 23.8% had lung metastases, 14.6% had peritoneal metastases, and 3.0% had bone metastases. In 83.8% of patients, metastases were located at one or more localizations (51.2% one localization, 24.9% two localizations, 7.6% three or more localizations).

Disease or treatment-related symptoms
At the time of PRO questioning, the fatigue score calculated from the EORTC QLQ-C30 reached an average of 47.2 (±26.6), indicating a noticeable burden with regard to an achievable score range of 0 (lowest burden) to 100 (highest burden). The pain score was 26.6 (±30.4) and the nausea and vomiting score was 12.7 (±20.3) on average.

Palliative treatment status
At the time of PRO questioning, most patients were in first-line palliative therapy (55.2%), 23.3% were at break after first-line, 15.5% were in second-line or at break after second-line, and 5.1% in third-line or later. The most current chemotherapy at the time of questioning was based on irinotecan in 44.8% of the patients, oxaliplatin in 37.4%, fluoropyrimidine monotherapy in 10.4%, and both irinotecan and oxaliplatin in 4.9%. The remaining patients (2.5%) had missing data. Monoclonal antibodies that were given in addition to chemotherapy were Vascular Endothelial Growth Factor (VEGF)-inhibitors (49.7%) and Epidermal Growth Factor Receptor (EGFR)-inhibitors (26.1%), 22.6% of patients received no additional antibody treatment. 40.9% of the patients had tumors with RAS wild-type tumors. The remaining patients (2.5%) had missing data.

Comparing the demographic and clinical characteristics of the included patients (n = 332, 76.7%), the PRO questioning took place within the first 12 months after first-line palliative treatment initiation. The remaining patients (n = 101, 23.3%) received the questionnaire up until 24 months after first-line palliative treatment initiation. The mean time for all interviewed patients was 8.2 months (median 5.2 months) after first-line palliative treatment initiation. The distribution of EQ-5D-5L utility scores was similar in the different time of questioning groups with a slightly steeper slope for patients who received the PRO questionnaire after 20 or 24 months (Fig. 2).

The included patients with advanced or metastatic CRC had an overall mean EQ-5D-5L utility score of 0.82 (±0.23). In comparison, the overall EQ-5D-5L VAS score and the overall EORTC global health status/QoL score were much lower with a mean of 62.05 (±22.23) and 56.66 (±21.66), respectively. Depending on the time of questioning after enrollment into the registry, the mean EQ-5D-5L score did not follow a linear trend but increased and decreased slightly between 0.83 (4 months) to 0.79 (20 months). The same findings were observed for the EQ-5D-5L VAS score with the highest score of 64.37 at 24 months and the lowest score of 57.41 at 20 months.
Table 1 Comparison of demographic and clinical characteristics of included and excluded CRC patients

|                          | Included patients (n = 433) | Excluded patients (n = 70) | p-value* |
|--------------------------|----------------------------|---------------------------|----------|
| Mean age in years (SD)   | 66.3 (9.5)                 | 69.4 (9.9)                | 0.01†    |
| Male                     | 61.2%                      | 68.6%                     | 0.24     |
| Mean BMI (SD)*           | 26.3 (5.2)                 | 26.0 (3.8)                | 0.55     |

Comorbidities at time of enrollment into registry

- Hypertension: 41.3% vs. 45.7%, p = 0.81
- Diabetes mellitus with end-organ damage: 0.7% vs. 2.9%, p = 0.27
- Diabetes mellitus without end-organ damage: 14.6% vs. 18.6%, p = 0.50
- Thyroid disease: 9.0% vs. 4.3%, p = 0.35
- Coronary heart disease: 8.3% vs. 8.6%, p = 1.00
- Tumor other than colorectal or lymphoma or leukemia: 7.9% vs. 7.1%, p = 1.00
- Chronic gastric or bowel disease: 6.7% vs. 1.4%, p = 0.18
- Adiposity: 6.5% vs. 2.9%, p = 0.44
- Chronic pulmonary disease: 5.8% vs. 4.3%, p = 0.90
- Anemia: 4.4% vs. 4.3%, p = 1.00
- Heart failure: 4.2% vs. 7.1%, p = 0.44
- Kidney disease: 3.5% vs. 8.5%, p = 0.15
- Urogenital disease: 3.2% vs. 5.7%, p = 0.07
- Cerebrovascular disease: 2.5% vs. 1.4%, p = 1.00
- Myocardial infarction: 2.5% vs. 0.0%, p = 0.47
- Peripheral artery occlusive disease: 2.1% vs. 1.4%, p = 1.00
- Mild liver disease: 1.4% vs. 0.0%, p = 1.00
- Moderate or severe liver disease: 0.7% vs. 0.0%, p = 1.00
- Polyneuropathy: 1.9% vs. 1.4%, p = 1.00
- Peptic ulcer disease: 0.5% vs. 0.0%, p = 1.00
- Connective tissue disease: 0.5% vs. 0.0%, p = 1.00
- Metastatic solid tumor other than colorectal: 0.5% vs. 0.0%, p = 1.00
- Hemiplegia: 0.2% vs. 0.0%, p = 1.00
- AIDS: 0.2% vs. 0.0%, p = 1.00
- Myocardial insufficiency: 0.0% vs. 0.0%, p = 1.00
- Dementia: 0.0% vs. 1.4%, p = 0.16

Localization of primary tumor

- Colon: 56.4% vs. 58.6%, p = 0.82
- Rectum: 43.4% vs. 41.4%, p = 0.82

Inoperable primary tumor

- 19.9% vs. 24.3%, p = 0.63

Tumor stage (UICC) at primary diagnosis

- I: 3.7% vs. 4.3%, p = 0.82
- II: 7.2% vs. 5.7%, p = 0.82
- III: 13.9% vs. 11.4%, p = 0.82
- IV: 66.5% vs. 72.9%, p = 0.82

Progression prior to questioning

- 0: 75.3% vs. 75.7%, p = 0.82
- 1: 16.6% vs. 12.9%, p = 0.82
- 2 or more: 4.4% vs. 7.1%, p = 0.82

*Borchert et al. Health Economics Review (2020) 10:40 Page 5 of 14
months as well as for the mean EORTC global health status/QoL score with the highest score of 61.27 at 16 months and the lowest score of 54.54 at month two. All in all, the descriptive statistics indicated that the time of questioning did not seem to have an effect on the PRO scores in our patient sample which was confirmed in the regression analyses.

The correlation between the three scores was statistically significant ($P < 0.0001$) but also indicated a wider distribution of the EQ-5D-5L VAS scores and the EORTC global health status/QoL scores compared to the EQ-5D-5L utility scores (Fig. 3).

The detailed analysis of the five EQ-5D-5L dimensions showed that the majority of patients did not have any problems with self-care, whereas approximately two-thirds of the patients reported slight, moderate, or severe problems in performing usual activities or were even unable to perform them. Pain or discomfort was reported in 60.5% of the patients. 56.4% stated to be anxious or depressed and half of the patients had problems in walking about (Fig. 4). No problems or difficulties in any of the dimensions were reported in 16.9% of the patients.

**Association of patient characteristics and HRQoL: descriptive analysis**

The boxplots in Fig. 5 illustrate the distribution of the EQ-5D-5L utility scores by patient characteristics in terms of minimum, 25th percentile, median, 75th percentile, and maximum. Regarding the demographic characteristics, the distribution was very similar showing no difference in terms of age groups and gender.

### Table 1 Comparison of demographic and clinical characteristics of included and excluded CRC patients (Continued)

|                                | Included patients ($n = 433$) | Excluded patients ($n = 70$) | $p$-value* |
|--------------------------------|-------------------------------|-----------------------------|------------|
| **Metastases**                 |                               |                             |            |
| Liver                          | 61.4%                         | 58.6%                       | 0.79       |
| Lung                           | 23.8%                         | 21.4%                       | 0.83       |
| Peritoneal                     | 14.6%                         | 20.0%                       | 0.49       |
| Bone                           | 3.0%                          | 2.9%                        | 0.93       |
| **Number of metastatic localizations prior to questioning** |                               |                             |            |
| 0                              | 10.9%                         | 7.1%                        |            |
| 1                              | 51.2%                         | 55.7%                       |            |
| 2                              | 24.9%                         | 27.1%                       |            |
| 3 or more                      | 7.6%                          | 5.7%                        |            |
| **Treatment line at time of questioning** |                               |                             | 0.93       |
| First-line palliative          | 55.2%                         | 60.0%                       |            |
| Break after first-line         | 23.3%                         | 20.0%                       |            |
| Second-line palliative or break after second-line | 15.5% | 14.3% |            |
| Third-line palliative or later | 5.1%                          | 5.7%                        |            |
| **Most current chemotherapy at time of questioning** |                               |                             |            |
| Irinotecan-based               | 44.8%                         | 44.3%                       |            |
| Oxaliplatin-based              | 37.4%                         | 34.3%                       |            |
| Fluoropyrimidine monotherapy   | 10.4%                         | 15.7%                       |            |
| Irinotecan plus oxaliplatin    | 4.9%                          | 2.9%                        |            |
| **Additional antibody treatment** |                               |                             | 0.68       |
| None                           | 22.6%                         | 28.6%                       |            |
| VEGF                           | 49.7%                         | 42.9%                       |            |
| EGFR                           | 26.1%                         | 27.1%                       |            |
| **RAS mutation status**        |                               |                             | 0.74       |
| Wild-type                      | 38.1%                         | 42.9%                       |            |
| Mutation                       | 40.9%                         | 40.0%                       |            |

*Independent t-test was applied for continuous variables. Chi²-test or Fisher’s exact test was applied for categorical variables
†Statistically significant at alpha = 0.05
Percentages may not add up to 100% due to patients with missing data
The categories of tumor history and metastases demonstrated a consistent distribution of HRQoL as well. Looking at the disease and treatment-related symptoms derived from the EORTC QLQ-C30, especially a high burden of fatigue and pain indicated a reduction in HRQoL. Patients undergoing third or later palliative treatment lines at the time of questioning had a remarkably lower HRQoL compared to patients in previous treatment lines. A decreased HRQoL was also shown for patients with two or more progressions in previous treatment lines than in patients with only one or no progression. For the noted comorbidities, patients with chronic pulmonary disease had the lowest HRQoL.

**Association of patient characteristics and HRQoL: regression analysis**

Table 3 reports the results derived from the tobit and OLS regression analyses of the relationship between the EQ-5D-5L utility score, the EQ-5D-5L VAS score, the EORTC Global Health Status/QoL score and patients’ demographic and clinical characteristics, respectively.

**Table 2** Mean EQ-5D-5L utility scores, the EQ-5D-5L VAS scores, and the EORTC global health status/QoL scores

| Time of questioning after enrollment | EQ-5D-5L Utility Score Mean | EQ-5D-5L Utility Score Standard Deviation (SD) | EQ-5D-5L VAS Score Mean | EQ-5D-5L VAS Score Standard Deviation (SD) | EORTC Global Health Status/ QoL Score Mean | EORTC Global Health Status/ QoL Score Standard Deviation (SD) |
|-------------------------------------|----------------------------|-----------------------------------------------|--------------------------|-------------------------------------------|--------------------------------------------|-------------------------------------------------|
| 0 months                            | 0.82                       | 0.23                                          | 60.56                    | 22.58                                     | 55.52                                      | 22.88                                           |
| 2 months                            | 0.81                       | 0.23                                          | 62.72                    | 20.09                                     | 54.54                                      | 21.25                                           |
| 4 months                            | 0.83                       | 0.22                                          | 58.85                    | 27.71                                     | 56.94                                      | 23.44                                           |
| 8 months                            | 0.82                       | 0.27                                          | 62.62                    | 22.66                                     | 57.49                                      | 22.30                                           |
| 12 months                           | 0.82                       | 0.19                                          | 67.13                    | 17.55                                     | 55.98                                      | 18.54                                           |
| 16 months                           | 0.82                       | 0.23                                          | 63.64                    | 23.34                                     | 61.27                                      | 18.80                                           |
| 20 months                           | 0.79                       | 0.24                                          | 57.41                    | 21.41                                     | 55.86                                      | 21.66                                           |
| 24 months                           | 0.80                       | 0.17                                          | 64.37                    | 21.94                                     | 58.83                                      | 23.52                                           |
| Overall                             | **0.82**                   | **0.23**                                      | **62.05**                | **22.23**                                 | **56.66**                                  | **21.66**                                      |
As opposed to OLS regression, coefficients from tobit regression analyses are not readily interpretable as effect sizes. Interpretation should consider whether the coefficient is negative or positive and whether it is statistically significant.

The results show that patients’ demographic characteristics did not affect HRQoL in any regression analysis. In addition, only few clinical characteristics had a statistically significant effect on HRQoL. In the tobit regression, hypertension, fatigue, and pain had a negative effect on the EQ-5D-5L utility score. In the OLS regression on the EQ-5D-5L VAS score, having completed the PRO questionnaire 12 or 24 months after enrollment into the registry and one prior progression had a positive effect on the EQ-5D-5L VAS score. Treatment in second-line or later, chronic gastric or bowel disease, fatigue, and pain, however, had a negative effect on the EQ-5D-5L VAS score. In the OLS regression of the EORTC Global Health Status/QoL score, chronic pulmonary diseases positively affected the EORTC Global Health Status/QoL score, but fatigue and pain had a negative effect.

In summary, all three regression analyses indicated that only few clinical characteristics influenced HRQoL. The symptoms fatigue and pain had a negative effect in all three regression analyses.

The marginal effects of the demographic or clinical characteristics from the tobit model were computed at the sample mean. Given the absence of significant differences in the impact of these characteristics over time, these marginal effects are based on the time invariant models reported in Table 3. They indicate that the statistically significant coefficients from the tobit regression only had a small effect on the EQ-5D-5L utility score: concomitant hypertension reduced the score by 0.052, each one-unit increase in the fatigue symptom scale by 0.003, and each one-unit increase in the pain symptom scale by 0.002.

Discussion

This cross-sectional application study linking registry data to PRO data investigated the HRQoL among patients with advanced or metastatic CRC in Germany and its association with patient demographic and clinical characteristics. In total, 758 questionnaires were sent to patients, 535 were returned, and 433 were finally included in the data analysis. Mean age of patients was 66.3 years and 61.2% were male. The overall mean EQ-5D-5L utility score was 0.82, the mean EQ-5D-5L VAS score was 62.05, and the mean EORTC global health status/QoL score was 56.66. The tobit regression analysis revealed that hypertension, fatigue, and pain had a significant negative impact on the HRQoL of advanced or metastatic CRC patients measured by the EQ-5D-5L utility scale \( (p < 0.01) \). Concomitant hypertension reduced the HRQoL score by 0.052, each 1-unit increase in the fatigue symptom scale by 0.003 and in the pain symptom scale by 0.002.

Huang and colleagues [17] assessed the HRQoL of 300 newly diagnosed patients with CRC in China’s Heilongjiang province. On average, the included patients were younger (mean age 59 vs 66 years) and diagnosed at an earlier tumor stage (stage IV 12% vs 67%) than in our study. Nevertheless, they found a mean EQ-5D-5L utility score of 0.62 compared to 0.82 in our study. The proportion of patients reporting problems was similar for the dimensions pain/discomfort (60% vs 60%), anxiety/depression (59% vs 56%), and mobility (46% vs 50%), but differed for self-care (49% vs 20%) and usual activities (53% vs 65%).

The level distribution in the EQ-5D-5L dimension anxiety/depression showed that about 56% of CRC
patients stated to be at least slightly to extremely anxious or depressed. It can be assumed that there is a relationship between physical and mental health as patients with CRC suffer physical burden of disease which might deteriorate their mental health status. Ohrnberger et al. [18] investigated the relationship between physical and mental health and possible mediators. They found that 8% of the total effect of physical health on mental health is mediated by physical health, with better physical health being correlated with higher physical activity which in turn has a positive impact on mental health [18].

Compared to the general population in Germany, problems in self-care (20.1% vs 6.4%) or pain and discomfort (60.5% vs 55.6%) were reported more frequently among patients with CRC. While 36.4% of the general German population did not report any problem or difficulty in any of the EQ-5D-5L dimensions [7], this proportion reached 16.9% among patients with CRC. Consequently, the patients with CRC analyzed in this study had a lower mean EQ-5D-5L utility score than the German general population (0.82 vs 0.92) [19]. However, this difference was smaller than expected and than observed for the EQ-5D-5L VAS score. Huber and colleagues [20] reported a mean EQ-5D-5L VAS score of 85.1 for the general population and Ludwig et al. from the EuroQoL group [7] found a mean score of 79.5 in their valuation study of the EQ-5D-5L. The mean score in the present study only reached 62.1 among patients with advanced or metastatic CRC. The relatively high and stable EQ-5D-5L utility scores may be explained by
Boxplots demonstrate the distribution of EQ-5D-5L utility scores in terms of minimum, 25th percentile, median, 75th percentile, and maximum.

Fig. 5 Distribution of EQ-5D-5L utility scores by patient characteristics.

---

Borchert et al. Health Economics Review (2020) 10:40
Table 3  Tobit and linear regression analyses of the relationship between health state utilities and patients’ characteristics

|                              | EQ-SD-5L Utility | EQ-SD-5L VAS | EORTC QoL |
|------------------------------|------------------|--------------|-----------|
|                              | \( \beta_{\text{Tobit}} \) | \( \beta_{\text{OLS}} \) | \( \beta_{\text{OLS}} \) |
| Intercept                    | 1.092            | 83.911       | 74.268    |
| Time of PRO questioning after enrollment into the registry |                   |              |           |
| 0 months ref                  | ref              | ref          | ref       |
| 2 months −0.017               | 0.033            | 4.349        | 3.120     |
| 4 months −0.001               | 0.039            | 1.538        | 3.699     |
| 8 months −0.029               | 0.036            | 0.704        | 3.278     |
| 12 months −0.027              | 0.037            | 8.225        | 3.497**   |
| 16 months 0.004               | 0.040            | 6.400        | 3.714     |
| 20 months −0.009              | 0.045            | 1.183        | 4.180     |
| 24 months 0.059               | 0.051            | 12.543       | 4.625**   |
| Age 0.001                     | 0.001            | −0.079       | 0.102     |
| Male 0.018                    | 0.021            | 1.719        | 1.947     |
| BMI 0.001                     | 0.002            | 0.200        | 0.207     |
| Primary tumor localization    |                  |              |           |
| Colon ref                     | ref              | ref          | ref       |
| Rectum −0.006                 | 0.021            | 0.189        | 1.916     |
| Inoperable primary tumor      | 0.007            | 0.025        | 2.245     |
| Number of progressions        |                  |              |           |
| 0 ref                         | ref              | ref          | ref       |
| 1 0.034                       | 0.038            | 7.763        | 3.615*    |
| \( \geq 2 \) 0.002           | 0.059            | 10.871       | 5.654     |
| Number of metastatic localizations |              |              |           |
| 0 ref                         | ref              | ref          | ref       |
| 1 −0.023                      | 0.034            | 0.656        | 3.143     |
| 2 −0.043                      | 0.038            | 0.080        | 3.519     |
| \( \geq 3 \) −0.053           | 0.049            | 0.522        | 4.539     |
| Palliative treatment line     |                  |              |           |
| First-line ref                | ref              | ref          | ref       |
| Break after first-line −0.047  | 0.029            | −4.536       | 2.657     |
| Second-line or later −0.053   | 0.042            | −11.939      | 4.000**   |
| Antibodies                    |                  |              |           |
| None ref                      | ref              | ref          | ref       |
| EGFR 0.012                    | 0.029            | −2.900       | 2.699     |
| VEGF 0.022                    | 0.025            | −2.343       | 2.358     |
| Comorbidities                 |                  |              |           |
| Adiposity −0.010              | 0.043            | 1.318        | 4.063     |
| Anemia −0.055                 | 0.045            | −0.436       | 4.394     |
| Chronic gastric or bowel disease −0.015 | 0.039 | −7.434 | 3.742* |
| Coronary heart disease 0.022  | 0.039            | −3.193       | 3.578     |
| Heart failure 0.029           | 0.051            | −1.782       | 4.688     |
| Hypertension −0.072           | 0.022**          | −3.202       | 2.074     |
| Moderate or severe kidney disease −0.026 | 0.056 | −0.262 | 5.268 |
the generic nature of the EQ-5D-5L. The questionnaire may not detect delicate nuances that affect the HRQoL of cancer patients with an advanced or metastatic disease as it was not tailored for this specific group of patients. The VAS score might depict the current HRQoL state more accurately since it is not restricted to the five dimensions. Furthermore, non-random missing data have to be considered since patients with severely impaired HRQoL are more likely not to return the questionnaires.

Looking at the EORTC global health status/QoL score, the included patients with advanced or metastatic CRC presented with a lower mean score than rectal cancer patients without disease progression from the Munich Cancer Registry (56.7 vs 65.3–69.4) [3] which might indicate that HRQoL decreases with disease status. The symptom scores for fatigue, pain, and nausea and vomiting, on the other hand, were higher than in our study, indicating higher levels of symptomatology, and ranged between 64.8 and 68.6 for fatigue (vs 47.2 in our study), between 80.4 and 82.2 for pain (vs 26.6 in our study), and between 95.3 and 97.2 for nausea/vomiting (vs 12.7 in our study) [3]. The EORTC module for CRC (EORTC-QLQ-C29) is not routinely applied for patients in the TKK because answering 29 questions in addition to the EORTC-QLQ-C30 would be too burdensome for patients in palliative treatment situation.

The regression analyses revealed that none of the demographic and only few of the clinical characteristics had a significant impact on the HRQoL of patients with CRC. This applied to the tobit regression on the EQ-5D-5L utility score, the OLS regression on the EQ-5D-5L VAS score, and the OLS regression on the EORTC global health status/QoL score. In line with this, a review by Marventano and colleagues reported that gender was not a significant determinant of colorectal cancer patients’ HRQoL and that results on age were controversial [21]. They also found that symptoms induced by cancer or its treatment such as fatigue had a significant negative impact on HRQoL, which was confirmed in our study as both the fatigue and the pain score negatively affected the HRQoL in all three regressions. On the contrary, the review showed that heart disease had a significant role on overall HRQoL [21], which was not confirmed in our study. The study by Huang and colleagues [17] also assessed determinants of HRQoL of patients with CRC using tobit regression. The study found that low HRQoL was associated with more advanced stages of CRC, presence of a stoma, surgery only treatments, and low socioeconomic status. Treatment with surgery only or information on socioeconomic status and stoma was not available in our study. Data on stoma are not routinely collected in the TKK as the registry focuses on the real-world treatment with systemic therapies in Germany and the presence of a stoma does not have an impact on the treatment of a patient. Our findings did not indicate that more advanced stages of CRC were associated with a lower HRQoL. As pointed out by Huang et al. [17], the evidence for the association between HRQoL and the stage of CRC from the literature is contradictory.

An explanation for the few significant determinants of HRQoL might be that seriously ill patients have accepted their fate (coping) and recognize their disease, treatment, and comorbidities as part of their daily life. This behavior was also observed among cystic fibrosis patients [22]. Another explanation could be that the investigated co-morbidities are under control and not relevant when compared to the symptoms associated with the cancer

### Table 3

Tobit and linear regression analyses of the relationship between health state utilities and patients’ characteristics (Continued)

|                      | EQ-5D-5L Utility | EQ-5D-5L VAS | EORTC QoL |
|----------------------|------------------|--------------|------------|
| **β_{Tobit}**        | **SE**           | **β_{OLS}**  | **SE**     | **β_{OLS}**  | **SE**     |
| Diabetes mellitus    | 0.031            | 0.029        | 1.637      | 2.746        | 2.521      | 2.502      |
| Chronic pulmonary    | −0.074           | 0.041        | 0.388      | 3.924        | 7.996      | 3.709**    |
| Thyroid disease      | −0.041           | 0.036        | 1.108      | 3.385        | 1.788      | 3.108      |
| Tumor                | 0.010            | 0.036        | 4.215      | 3.435        | −4.265     | 3.134      |
| Disease and          |                  |              |            |              |            |            |
| treatment related    |                  |              |            |              |            |            |
| symptoms (EORTC      |                  |              |            |              |            |            |
| QLQ-C30 symptom      |                  |              |            |              |            |            |
| scales)              |                  |              |            |              |            |            |
| Nausea and vomiting  | 0.000            | 0.001        | −0.011     | 0.051        | −0.058     | 0.047      |
| Fatigue              | −0.004           | 0.000**      | −0.384     | 0.044**      | −0.472     | 0.040**    |
| Pain                 | −0.003           | 0.000**      | −0.170     | 0.036**      | −0.121     | 0.033**    |
| σ                    | 0.177            | 0.007**      |            |              |            |            |
| Pseudo-R²            | 0.35             |              |            |              |            |            |
| Adjusted R²          |                  | 0.386        | 0.485      |              |            |            |

*P < 0.05; **P < 0.01

a without organ impairment

b other than colorectal, lymphoma or leukemia
and its treatment. Furthermore, as mentioned above, data on patients with severely reduced HRQoL might be under-represented in our study because these patients were less likely to return the questionnaires.

There are two limitations that should be mentioned here in addition. First, specific patient characteristics such as comorbidities were only documented at start of palliative treatment. Consequently, changes in these characteristics until PRO questioning were not available and misclassification bias cannot be excluded. Second, confounding by unmeasured variables cannot be ruled out. Marventano and colleagues, for example, found in their review that depression, urinary disorder, a weak social network and a low income negatively affected HRQoL in patients with CRC [21], but these parameters were not collected in our study.

Conclusion
This study linking clinical registry data to HRQoL data showed only a slight reduction in HRQoL of patients with advanced or metastatic CRC when compared to the general population or rectal cancer patients without disease progression. The regression analyses revealed that none of the included demographic and clinical characteristics had a significant impact on the HRQoL of patients with CRC except for the disease or treatment-related symptoms fatigue and pain. The relatively high and stable EQ-5D-5L utility scores could be caused by a high coping effect, by bias due to non-random missing data or by the generic character of the questionnaire not detecting delicate nuances. The VAS score seemed to depict the current HRQoL state more accurately since it is not restricted to five dimensions. However, this study demonstrates the feasible opportunity to collect additional data of interest in ongoing registries and that management of disease and treatment-related symptoms is of utmost importance to advanced and metastatic CRC patients.

Abbreviations
AMNOG: Act on the Reform of the Market for Medicinal Products (German benefit assessment); BMI: Body Mass Index; CRC: Colorectal cancer; EGFR: Epidermal Growth Factor Receptor; EORTC QLQ-C30: Quality of Life Questionnaire Core 30 version 3.0 of the European Organization for Research and Treatment of Cancer; EQ-5D-5L: EuroQol five-dimension questionnaire using a five-point scale; G-BA: Head of the Joint Federal Committee; HRQoL: Health related quality of life; iOMEDICO: International Organisation of Medical Oncology; IQWiG: Institute for Quality and Efficiency in Health Care; OLS: Ordinary least squares; PRO: Patient-reported outcomes; QALYs: Quality adjusted life years; RAS: Rat sarcoma; SD: Standard Deviation; TKK: Tumor Registry Colorectal Cancer; UIUC: Union for International Cancer Control; VAS: Visual analogue scale; VEGF: Vascular Endothelial Growth Factor

Authors’ contributions
All authors contributed to the study conception and design. Data collection was performed by NW, MJ, EE, AS, and NM. Material preparation and data analysis were performed by KB, CJ, JA, and TM. The first draft of the manuscript was written by KB and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by the EuroQol Group. Financial support for this study was provided entirely by a contract with the EuroQol Group. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report. The following author is employed by the sponsor: Prof. Wolfgang Greiner.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Restrictions apply to the availability of the data that supports the findings of this study, and so are not publicly available.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ethics Committee of the medical association of Baden-Württemberg, reference number: F-2010-050) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication
Informed consent was obtained from all individual participants included in the study.

Competing interests
KB, CJ, JA, and TM are employees of Xcenda GmbH. Xcenda GmbH received research grants from the EuroQol group to design and conduct the study, to perform the statistical analyses, and to write the manuscript. WG is member of the EuroQol group and received research grants from the EuroQol group to design and conduct the study, to perform the statistical analyses, and to write the manuscript.

NW, MJ, EE, AS, and NM declare that they have no conflict of interest.

Author details
1Xcenda GmbH, Hannover, Germany. 2iOMEDICO AG, Freiburg im Breisgau, Germany. 3Kreiskrankenhaus Torgau, Torgau, Germany. 4Medizinisches Versorgungszentrum für Blut- und Kreiselerkrankungen, Potsdam, Germany. 5Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg im Breisgau, Germany. 6Universität Bielefeld, Bielefeld, Germany.

Received: 27 April 2020 Accepted: 26 November 2020
Published online: 12 December 2020

References
1. Robert Koch Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland (2017). Krebs in Deutschland 2013/2014. https://www.krebsdaten.de/Krebs/DF/Content/Ublikationen/Krebs_in_Deutschland/kid_2017/krebs_in_deutschland_2017.pdf?__blob=publicationFile.
2. Emmert M, Pohl-Derrick K, Wein A, Dorse F, Merkel S, Boxberger F, et al. Palliative treatment of colorectal cancer in Germany: cost of care and quality of life. Eur J Health Econ. 2013;14(4):629–38. https://doi.org/10.1007/s10198-012-0408-5.
3. Engel J, Kerr J, Schlesinger-Raab A, Eckel R, Sauer H, Holzel D. Quality of life in rectal cancer patients: a four-year prospective study. Ann Surg. 2003; 238(2):203–13. https://doi.org/10.1097/01.sla.0000080823.38569.b0.
4. Schwenkglenks M, Matter-Walstra K. Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):207–19. https://doi.org/10.1586/14737167.2016.1146594.
5. Staack, F. (2016). GQA-Chef will Vorfahrt für Lebensqualität. ÄrzteZeitung.
6. Marschner N, Arnold D, Engel E, Hutzschemekeler U, Raab J, Freier W, et al. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - results from a prospective cohort study. Clin Epidemiol. 2015;7:295–303. https://doi.org/10.2147/CLEP.S73857.
7. Ludwig K, von der Schulenburg JM, Geiner W. German value set for the EQ-SD-SL. [journal article]. PharmacoEconomics. 2018;36(6):663–74. https://doi.org/10.1007/s40273-018-0615-8.

8. EuroQol Group (2015). EQ-SD-SL User Guide. Basic information on how to use the EQ-SD-SL instrument.

9. Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 69:79–88. https://doi.org/10.1016/j.jclinepi.2015.08.007.

10. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCM, Kaasa S, Klee MC, Osoba D, Razavi D, Rohe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85, 365–376.

11. EORTC Quality of Life Group (Copyright 1995). EORTC QLQ-C30 (version 3).

12. Fayers PM, A. N., Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group, (2001). EORTC QLQ-C30 Scoring Manual (Third Edition).

13. Austin PC, Escobar M, Kopec JA. The use of the Tobit model for analyzing measures of health status. Qual Life Res. 2000;9(8):901–10.

14. Austin PC. A comparison of methods for analyzing health-related quality-of-life measures. Value Health. 2002;5(4):329–37.

15. Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of Cancer therapy - breast (FACT-B) to the 5-level EuroQol group’s 5-dimensional questionnaire (EQ-SD-SL) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12:180.

16. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-SD (UKPDS 62). Med Decis Mak. 2002;22(4):340–9.

17. Huang W, Yang J, Liu Y, Liu C, Zhang X, Fu W, et al. Assessing health-related quality of life of patients with colorectal cancer using EQ-SD-SL: a cross-sectional study in Heilongjiang of China. BMJ Open. 2018;8(12):e022711.

18. Ohnhenber J, Eicher E, Sutton M. The relationship between physical and mental health: A mediation analysis. Soc Sci Med. 2017;195:42–9.

19. Hinz A, Kohlmann T, Stobel-Richter Y, Zenger M, Bashler E. The quality of life questionnaire EQ-SD-SL: psychometric properties and normative values for the general German population. Qual Life Res. 2014;23(2):443–7. https://doi.org/10.1007/s11136-013-0498-2.

20. Huber MB, Felix J, Vogelmann M, Leidl R. Health-related quality of life of the general German population in 2015: results from the EQ-SD-SL. Int J Environ Res Public Health. 2017;14(4). https://doi.org/10.3390/ijerph14040426.

21. Marventano S, Forjaz MJ, Grosso G, Mistretta A, Giorgianni G, Platania A, et al. Health related quality of life in colorectal cancer patients: state of the art. BMC Surg. 2013;13(Suppl 2):S15.

22. Eidt-Koch D, Wagner TOF, Mittendorf T, Graf von der Schulenburg JM. Outpatient medication costs of patients with cystic fibrosis in Germany. Appl Health Econ Health Policy. 2010.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.